In current clinically-validated biomarker tests, 30% ctDNA is the approximate limit of detection for deletions which constitute a major class of genomic eligibility for targeted drugs in prostate cancer (e.g., BRCA2 and PARP inhibitors, PTEN and AKT/PI3K inhibitors)23,61,63. This evidence concerns the gene BRCA2 and prostate carcinoma.